Credit: Shutterstock photoDBV Technologies, a French biotech developing immunotherapy patches that treat food allergies, announced terms for its US IPO on Wednesday. The Bagneux, France-based company is currently listed on the Euronext Paris under the symbol DBV. It plans to offer 4.3 million ADSs, and at $23 per ADS, the price as of October 14, DBV Technologies would command a fully diluted market value of $964 million.
DBV recently announced topline results for its Phase 2b clinical trial of Viaskin Peanut, an electrostatic patch that delivers biologically active compounds to the immune system through the skin. Viaskin peanut obtained Fast Track Designation from the FDA, and expects to begin Phase 3 trials in the 1Q16. The company also plans to initiate a Phase 1 trial in the 4Q14 for cow's milk protein allergy in children.
Primary shareholders include Sofinnova Partners (14% pre-IPO stake), Bpifrance (13%), Baker Brothers Investments (6%) and CEO Pierre-Henri Benhamou (4%).
DBV Technologies, which was founded in 2002 and booked $7 million in revenue for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol DBVT. Citi, Leerink Partners and Bryan, Garnier & Co are the joint bookrunners on the deal. No pricing date was disclosed.
The article Peanut allergy biotech DBV Technologies sets terms for $98 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
